VENTRIPOINT DIAGNOSTICS LTD. ("VPT")
BULLETIN TYPE: Prospectus-Unit Offering
BULLETIN DATE: November 01, 2021
TSX Venture Tier 2 Company
Effective October 14, 2021, the Company's final short form prospectus dated October 13, 2021, qualifying the distribution of up to 13,470,000 units (the "Units") of the Company, excluding underwriters' over-allotment option, was filed with and accepted by TSX Venture Exchange (the "Exchange"), and filed with and receipted by the Ontario Securities Commission as principal regulator. Under Multilateral Instrument 11-102 - Passport System the prospectus is deemed to have been filed with and receipted by each of the British Columbia, Alberta and Saskatchewan Securities Commissions.
The Exchange has been advised that closing occurred on October 20, 2021 for aggregate gross proceeds of CDN$8,055,060 (including the underwriters' over-allotment option that was exercised in full).
Offering: 15,490,500 Units (includes 2,020,500 Units of underwriter's over-allotment option). Each Unit consists of one common share and one common share purchase warrant, with each warrant being exercisable into one common share at CDN$0.70 for a 60-month period, subject to accelerated expiry in certain circumstances.
Unit Price: CDN$0.52 per Unit.
Underwriter(s): Leede Jones Gable Inc. and Stifel Nicolaus Canada Inc.
Underwriter(s) Commission: An aggregate of CDN$535,774 in cash and 1,030,335 non-transferrable broker warrants. Each broker warrant entitles the holder to acquire one Unit at CDN$0.52 for a 60-month period.
For further details, please refer to the Company's Short Form Prospectus dated October 13, 2021 and news releases dated September 27, 2021, September 28, 2021, October 01, 2021 and October 20, 2021.
________________________________________________
|
|
